- Home
- FOXA vs RPRX Comparison
FOXA vs RPRX Comparison
Compare FOXA & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FOXA | RPRX |
|---|---|---|
| Founded | 2018 | 1996 |
| Country | United States | United States |
| Employees | 10400 | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0B | 22.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FOXA | RPRX |
|---|---|---|
| Price | $52.23 | $52.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | ★ $71.57 | $51.40 |
| AVG Volume (30 Days) | ★ 5.9M | 3.2M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | 0.89% | ★ 1.90% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.67 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | $1.78 | $38.63 |
| Revenue Next Year | $4.24 | $4.73 |
| P/E Ratio | ★ $13.70 | $78.89 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $50.68 | $34.63 |
| 52 Week High | $76.39 | $56.50 |
Technical Indicators
Market Signals| Indicator | FOXA | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 27.39 | 45.83 |
| Support Level | N/A | $35.33 |
| Resistance Level | $66.74 | $56.50 |
| Average True Range (ATR) | 2.54 | 1.42 |
| MACD | -1.87 | -0.40 |
| Stochastic Oscillator | 8.38 | 33.83 |
Price Performance
Historical ComparisonAbout FOXA Fox Corporation
Fox operates in two segments: cable networks and television. Cable networks primarily includes Fox News, Fox Business, and several pay-TV sports stations. Television primarily includes the Fox broadcast network, 29 owned and operated local television stations, of which 18 are affiliated with the Fox network, and streaming platform Tubi, which is not subscription-based and is completely ad-supported. Fox effectively sold most of its entertainment assets to Disney in 2019, so it no longer creates entertainment content and relies heavily on live news and sports, with nearly all tied to the pay-TV bundle. The Murdoch family controls Fox.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.